Amarantus Bioscience Holdings Inc (AMBS)

[JPetroInc]

why would Dr. Robert Stern of BU Medical Center and Amarantus' newly appointed AZ Scientific Advisory Board member be working concurrently with Amarantus - as well as Aethlon Medical & Exosome Sciences on a CTE Dx discovery platform at BUMC, on former NFL players?

are these NFL players the same for both of the CTE Dx studies - if so, why?

*************************************************************************************************************************************************************************

Amarantus Forms AZ Disease Diagnostics Scientific Advisory Board January 22, 2015 07:00 ET | Source: Amarantus BioScience Holdings, Inc.

http://globenewswire.com/news-release/2015/01/22/699158/10116471/en/Amarantus-Forms-Alzheimer-s-Disease-Diagnostics-Scientific-Advisory-Board.html#sthash.herEgK9t.dpuf

*************************************************************************************************************************************************************************

Dr. Robert Stern - Amarantus new SAB Member

http://www.amarantus.com/about/alzheimers-disease-diagnostics-sab

Robert A. Stern, Ph.D.

Dr. Stern’s major focus of research expertise is on the long-term effects of repetitive brain trauma in athletes, including the neurodegenerative disease, Chronic Traumatic Encephalopathy (CTE). He is a Professor of neurology, neurosurgery, anatomy and neurobiology at Boston University School of Medicine, Director of the Clinical Core of the Boston University Alzheimer’s Disease Center, and Director of Clinical Research for the CTE Center at Boston University. Both the NIH and the Department of Defense have funded his work on developing methods of detecting and diagnosing CTE during life, as well as examining potential genetic and other risk factors for this disease. Dr. Stern’s other major areas of funded research include the assessment and treatment of Alzheimer’s disease, the cognitive effects of chemotherapy in the elderly, thyroid-brain relationships, and driving and dementia. He has published on various aspects of cognitive assessment and is the senior author of many widely used neuropsychological tests, including the Neuropsychological Assessment Battery (NAB).

Dr. Stern was formerly on the faculty at University of North Carolina, where he was the Associate Director of the NIMH-funded Mental Health Clinical Research Center, and Director of the Neurobehavioral Assessment Core. He was also on the faculty at Brown Medical School, where he was Associate Professor of Psychiatry and Neurology, as well as Director of Neuropsychology and the Memory and Cognitive Assessment Program at Rhode Island Hospital. Dr. Stern has received several NIH and other national grants and has published over 250 journal articles, chapters, and abstracts. He is a Fellow of both the American Neuropsychiatric Association and the National Academy of Neuropsychology. He is on several editorial boards and serves on the Medical and Scientific Advisory Boards of the MA/NH Chapter of the Alzheimer’s Association and the Sports Legacy Institute. Dr. Stern is also a member of the Mackey-White Traumatic Brain Injury Committee of the NFL Players Association. He has testified before the U.S. Senate Special Committee on Aging and frequently appears in national and international print and broadcast media for his work on CTE and AD.

*************************************************************************************************************************************************************************

Dr. Robert Stern & Amarantus Establishes LymPro Research Collaboration with BU School of Medicine for LymPro CTE study in Former NFL Players - Jan. 29, 2014

http://ir.amarantus.com/company-news/detail/1094/amarantus-establishes-lympro-research-collaboration-with-boston-university-school-of-medicine

SAN FRANCISCO, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it is establishing a research collaboration with researchers at Boston University School of Medicine (BUSM). The Company will work together with BUSM Professor of Neurology and Neurosurgery Dr. Robert Stern to evaluate the feasibility of using the LymPro Test ® as a blood based test to identify patients early in the disease process of the neurodegenerative diseases, Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD).

"We are pleased to be establishing this collaboration to evaluate the potential of LymPro in this emerging area of medical interest," said Gerald E. Commissiong, President and CEO of Amarantus. "While the research is early in nature, there is a strong scientific basis to believe that the cell cycle dysregulation that LymPro measures in Alzheimer's patients may have relevance to Traumatic Brain Injury and CTE. We are hopeful the information generated from this study will provide further insights for the field as we learn more about CTE."

Dr. Stern, who is the Clinical Core Director at the BU Alzheimer's Disease Center, has grant funding from the National Institutes of Health (NIH) to fund his work on developing methods of detecting and diagnosing CTE during life; this was the first grant for CTE ever funded by NIH (co-funded by the National Institute of Neurological Disorders and Stroke, the National Institute on Aging, and the National Institute of Child Health and Human Development). As part of the study, Stern and his colleagues have already examined over 70 former NFL players and 20 same age elite non-contact sport athletes.

"Cell cycle dysregulation is an emerging area of interest in Alzheimer's disease and Traumatic Brain Injury," said Dr. Stern. "We are hopeful the data gathered from this study will inform future studies into this important and emerging field of medical science."

*************************************************************************************************************************************************************************

Dr. Robert Stern and Aethlon Medical with Exosome Sciences Announce Clinical Collaboration with BU CTE Center To Advance Diagnostic Candidate to Detect CTE in Former NFL Players - September 26, 2014

http://www.exosomesciences.com/NewsList.aspx

SAN DIEGO, PRINCETON, N.J. and BOSTON, Sept. 26, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that a clinical collaboration with the Boston University (BU) CTE Center has been established to advance a blood-based diagnostic candidate that could identify Chronic Traumatic Encephalopathy (CTE) in living individuals.

CTE is a progressive neurodegenerative disorder that has been found at autopsy in former National Football League (NFL) players. At present, CTE can only be diagnosed through postmortem autopsy. The BU CTE Center has been a leading CTE research center since the disease was first defined.

Aethlon Medical develops targeted therapeutic devices to address infectious disease, cancer and neurodegenerative disorders. ESI (Aethlon subsidiary) develops exosome-based solutions to diagnose and monitor cancer and neurodegenerative disorders. Earlier this year, Aethlon disclosed that ESI researchers had successfully isolated exosome-based biomarkers transporting tau protein across the blood-brain barrier and into the circulatory system. The hallmark of CTE is an excess of accumulation of tau in the brain.

In the study, ESI researchers are evaluating and defining exosome and exosomal tau populations in blood samples collected from participants enrolled in the DETECT (Diagnosing and Evaluating Traumatic Encephalopathy Using Clinical Tests) study, under the direction of Dr. Robert Stern, Director of Clinical Research at the BU CTE Center.

The DETECT study is the first research project on CTE ever funded by the National Institutes of Health (NIH), with support from the National Institute of Neurologic Diseases and Stroke (NINDS), the National Institute on Aging (NIA), and the National Institute of Child Health and Human Development (NICHD). The ultimate goal of the study is to develop methods, including blood-based tests, that could diagnose CTE during life. The study has enrolled former NFL players (ages 40-69) and same-age "control" athletes who played non-contact sports.

"Our colleagues at the CTE Center are premier thought leaders in the CTE field and have been instrumental in changing how the NFL and other high-risk sports respond to head trauma," stated Aethlon Medical CEO Jim Joyce, who also serves as Executive Chairman of ESI. "We are truly grateful for the opportunity to establish a blood-based test that could identify CTE in living individuals."